Fedwatch: How Few i...
Health Care: Drugs
Vanda Pharmaceuticals Inc. (VNDA: NASDAQ)
$10.92 -0.31 | -2.76%
06/18/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 11.23 |
| 52 Week High | 13.30 |
| 52 Week Low | 2.92 |
| Avg. Daily Vol. (Mil) | 0.77 |
| Beta (3 year) | 1.81 |
| Share Related Items | |
| Mkt Cap (Mil) | 318.33 |
| Shares Out (Mil) | 28.35 |
| Float (Mil) | 27.84 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.50 |
| Current Ratio | 3.60 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 9.75 |
| Price/Book | 49.12 |
| Price/Cash Flow | -14.90 |
| Per Share Data | |
| Earnings | -0.85 |
| Sales | 1.15 |
| Book Value | 0.23 |
| Cash Flow | -0.76 |
| Business Summary | |
|---|---|
| Vanda Pharmaceuticals Inc. is a biopharmaceutical Company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. | |
| General Information | |
| 2200 Pennsylvania Avenue NW
Suite 300 E Washington, WA 20037 |
|
| www.vandapharmaceuticals.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 40 | |
| CEO: Dr. Mihael Hristos Polym | |
| Short Interest | |
| Current Month (Mil) | 1.18 |
| Previous Month (Mil) | 0.79 |
| Short Interest Ratio (Days) | 1.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -19.10 |
| Return on Investments | -368.00 |
| Profitability | |
| Gross Margin | 99.60 |
| EBIT Margin | -76.10 |
| Profit Margin | -73.10 |
Portfolios with VNDA
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics 15
- ContributorHot Biotech Stocks Traded b...
- ContributorBreakout Stocks Of The Week...
- UserWatching
- Contributor10 Unloved Stocks to Rise U...
- Contributor10 Companies That Missed Ea...
- UserJim Luterek Portfolio 1
- Userjph1020 Portfolio 1
- UserHot Biotech Stocks
- Userbigboyjohno Portfolio 1
Latest VNDA Headlines from TheStreet
- Commit To Purchase Vanda Pharmaceuticals At $7, Earn 21.1% Annualized 06.06.13 | 01:06 pm
- Biotech Stock Mailbag: Amarin 04.23.12 | 07:04 am
- Vanda Pharmaceuticals Inc. Stock Downgraded (VNDA) 11.08.11 | 05:11 am
- Biotech Stock Mailbag: Exelixis 10.28.11 | 06:10 am
- 5 Stocks Setting Up to Break Out 04.18.11 | 07:04 am
- Biotech Stock Mailbag: Bio-Hazards 03.25.11 | 07:03 am
- Vanda Pharmaceuticals Inc. Stock Upgraded By TheStreet Ratings (VNDA) 02.11.11 | 05:02 pm
- Vanda's Fanapt Falls Flat 02.04.11 | 11:02 am
- Clinical Data: Bulls and Bears Round Two 01.25.11 | 06:01 am
- 10 Unloved Stocks to Rise Up to 120% 12.16.10 | 06:12 am
Press Releases for VNDA
- Vanda Presents Data From Phase III Studies That Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder - PR Newswire 06.17.13 | 07:06 pm
- Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder - PR Newswire 06.05.13 | 09:06 pm
- Vanda Pharmaceuticals To Present At The Jefferies 2013 Global Healthcare Conference - PR Newswire 05.31.13 | 04:05 pm
- Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind - PR Newswire 05.31.13 | 06:05 am
- Vanda To Present Tasimelteon Non-24 Phase III Data At Two Medical Meetings - PR Newswire 05.30.13 | 08:05 pm
- Vanda Pharmaceuticals Named The 2013 Life Science Firm Of The Year By The Tech Council Of Maryland - PR Newswire 05.23.13 | 10:05 pm
- Vanda Pharmaceuticals To Announce First Quarter 2013 Financial Results On May 9, 2013 - PR Newswire 04.18.13 | 07:04 am
- Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer - PR Newswire 04.17.13 | 07:04 pm
- Vanda Pharmaceuticals To Present At The BioCentury Future Leaders In The Biotech Industry Conference - PR Newswire 04.04.13 | 07:04 pm
- Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind - PR Newswire 03.25.13 | 06:03 am
Partner Headlines for VNDA
- Stock Watch Wednesday, 19 December - Seeking Alpha 12.19.12 | 09:12 am
- Cashed Up Biotech Vanda Could Keep On Falling - Seeking Alpha 09.05.12 | 09:09 am
- 4 Cash Loaded Biotech Stocks With Little Debt - Seeking Alpha 08.30.12 | 09:08 am
- Healthcare Stocks To Watch This Week - Seeking Alpha 10.12.11 | 08:10 am
- 6 Deeply Undervalued Biotech Stocks - Seeking Alpha 07.27.11 | 09:07 am
- What FDA's Delay of Probuphine Trial Means for Titan Pharmaceuticals - Seeking Alpha 06.20.11 | 08:06 am
- As the Market Dips, It's Time to Look for Biotech Sector Deals - Seeking Alpha 06.12.11 | 09:06 am
- Titan Pharmaceuticals: $2 Mark Broken - Looks to Hold - Seeking Alpha 05.26.11 | 09:05 am
- 6 Cash Rich Biotech Stocks With Catalysts - Seeking Alpha 04.08.11 | 08:04 am
- UPDATE 2-US FDA chemist, son charged with insider trading - Reuters 03.29.11 | 05:03 pm
